Back to top
more

Mesa Laboratories (MLAB)

(Real Time Quote from BATS)

$62.33 USD

62.33
141,323

+4.89 (8.51%)

Updated Aug 6, 2025 02:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Mesa Labs (MLAB) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -5.69% and -2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mettler-Toledo (MTD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Mettler-Toledo (MTD) delivered earnings and revenue surprises of +5.32% and +2.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mesa Labs (MLAB) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -18.91% and 1.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sensus Healthcare (SRTS) delivered earnings and revenue surprises of -500% and 14.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Steris (STE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 5.79% and 0.09%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -46.67% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of -70% and 9.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Mesa Labs (MLAB) a New Strong Buy Stock

by Zacks Equity Research

Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Masimo Corporation (MASI) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Masimo (MASI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Why Mesa Labs (MLAB) Might be Well Poised for a Surge

by Zacks Equity Research

Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 8.98% and 4.91%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -1.21% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock

by Zacks Equity Research

Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

New Strong Buy Stocks for August 26th

by Zacks Equity Research

QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024.

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Value Stocks to Buy for April 8th

by Zacks Equity Research

SM and MLAB made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2023.

Zacks Equity Research

Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.98% and 2.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 3.12% and 11.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bear of the Day: Mesa Labs (MLAB)

by Kevin Cook

Mesa diagnostics gains importance among big pharma so we want to watch this dip

Zacks Equity Research

Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 5.99% and 2.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?